Latest News and Press Releases
Want to stay updated on the latest news?
-
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of...
-
-- Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine -- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology...
-
-- Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc.,...
-
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
-
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
-
-- Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online -- SOUTH SAN FRANCISCO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a...
-
SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that one of its...
-
-- Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a...
-
SOUTH SAN FRANCISCO, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues,...
-
SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the...